Exagen Inc Entered Into Amendment No. 1 To That Certain Sales Agreement, Dated September 15, 2022; May, From Time To Time, Continue To Issue, Sell Shares Of Common Stock, Having An Aggregate Offering Price Of Up To $50M
Portfolio Pulse from Benzinga Newsdesk
Exagen Inc. has disclosed in an SEC filing that it may continue to issue and sell shares of its common stock from time to time, with an aggregate offering price of up to $50 million.
November 17, 2023 | 9:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Exagen Inc. may issue new shares of common stock up to $50 million, which could lead to dilution of existing shareholders' equity.
The potential issuance of new shares by Exagen Inc. typically suggests a dilutive effect on current shareholders' equity. This can lead to a negative perception in the short term as the market adjusts to the increased share supply and potential dilution of earnings per share.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100